SGPL1 and myeloid sarcoma: A key finding of the study was that the risk allele-carrying EVI5 protein interacts with sphingosine 1-phosphate lyase (SGPL1), a key enzyme in the formation of the S1P gradient that is important for the adaptive immune response and the treatment of MS [83].